Skip to Content

Tranylcypromine Pregnancy and Breastfeeding Warnings

Tranylcypromine is also known as: Parnate

Tranylcypromine Pregnancy Warnings

Tranylcypromine has not been formally assigned to a pregnancy category by the FDA. Tranylcypromine crosses the placenta in rats. There are no controlled data in human pregnancy. Tranylcypromine is only recommended for use during pregnancy when benefit outweighs risk.

In a review of 21 mother-child pairs exposed to monoamine oxidase inhibitors in the first trimester by the Collaborative Perinatal Project, 13 of the pairs were exposed to tranylcypromine. Of the 21 infants, three had malformations. However, details with respect to tranylcypromine exposure were unavailable. A 41-year-old woman treated with tranylcypromine (100 mg/day), pimozide (1 mg/day) and diazepam (5 to 10 mg/day) for severe depression delivered a stillborn fetus at 31-weeks gestation. Upon examination the stillborn infant revealed hypertelorism, a large atrioventricular septal defect, a single coronary ostium, and a right pulmonary isomerism. In addition, the placenta had multiple infarcts that may have contributed to the fetal death. In her second pregnancy, an ultrasound at 19-weeks gestation showed a fetus with a 'lemon-shaped' head. In another case, a female infant was delivered at 38-weeks gestation because of poor growth. The infant also had multiple defects including hypertelorism, low-set overfolded ears, cleft palate, micrognathia, distal phalangeal hypoplasia, agenesis of the corpus callosum, and atrioventricular septal defect. These outcomes have been attributed to tranylcypromine and possibly a result of reduced uterine and placental blood flow.

See references

Tranylcypromine Breastfeeding Warnings

Tranylcypromine is excreted into human milk. There are no data on the use of tranylcypromine during lactation, and the potential effects in a nursing infant are unknown. Tranylcypromine is only recommended for use during lactation when benefit outweighs risk.

See references

References for pregnancy information

  1. "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
  2. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 7th ed." Philadelphia, PA: Lippincott Williams & Wilkins (2005):

References for breastfeeding information

  1. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 7th ed." Philadelphia, PA: Lippincott Williams & Wilkins (2005):
  2. "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.